Screener / SEC EDGAR /CIK 0000313143 /10-K filed May 20, 2026, compared with May 21, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Haemonetics Corp HAE

Compare with peers Embed

HAE among the 162 companies we cover

Where it stands · the better end on the right. The band holds the middle half; the line is the median.

All 162
Sales growth
+4.8%+20.2%
-2.0%142nd of 155 · median +10.5%
Net margin
-4.1%15.3%
7.5%73rd of 154 · median 6.8%
Return on equity
-5.2%18.5%
11.6%62nd of 144 · median 9.2%
Free cash flow margin
2.3%19.2%
21.6%28th of 145 · median 10.0%
Debt / equity (less is better)
1.160.42
1.2787th of 108 · median 0.69

HAE and 9 peers, year by year

The 9 Health care companies closest to HAE in revenue over the last twelve months. Every number is from the 10-K and links to it in SEC's Inline XBRL viewer.

Choose the peers

Health care companies (up to 9):

Each company's latest fiscal year
CompanyYearRevenueSales growthGross marginOperating marginNet marginFCF marginReturn on equityDebt / equity
HAE Haemonetics Corp FY2026 $1.3B−2.0%59.0%11.7%7.3%19.5%12.2%1.56
PGNY Progyny, Inc. FY2025 $1.3B+10.4%23.6%6.6%4.5%14.9%11.3%-
MDGL Madrigal Pharmaceuticals, Inc. FY2025 $958.4M+432%-−31.3%−30.1%−19.8%−47.8%0.56
GH Guardant Health, Inc. FY2025 $982.0M+32.9%-−44.5%−42.4%−23.7%n/mn/m
ADUS Addus HomeCare Corp FY2025 $1.4B+23.2%32.5%9.7%6.7%7.3%8.8%0.11
LIVN LivaNova PLC FY2025 $1.4B+10.7%67.7%14.4%−17.5%12.5%−20.2%0.31
INSM INSMED Inc FY2025 $606.4M+66.7%-−205.6%−210.5%−159.6%−172.8%0.74
SHC Sotera Health Co FY2025 $1.2B+5.7%55.5%-6.7%12.8%12.9%3.53
TECH Bio-Techne FY2026 $1.2B−0.4%65.8%20.7%15.0%21.7%8.6%0.09
PEN Penumbra Inc FY2025 $1.4B+17.5%67.1%13.5%12.7%12.5%12.4%-

Each company, year by year

Bars: revenue, each company on its own scale. Line: net margin, on one scale for all. FY2017 to FY2026 · 10-K XBRL

HAEHaemonetics Corp
FY2017 revenue $886.1MFY2018 revenue $903.9MFY2019 revenue $967.6MFY2020 revenue $988.5MFY2021 revenue $870.5MFY2022 revenue $993.2MFY2023 revenue $1.2BFY2024 revenue $1.3BFY2025 revenue $1.4BFY2026 revenue $1.3B FY2017 net margin −3.0%FY2018 net margin 5.0%FY2019 net margin 5.7%FY2020 net margin 7.7%FY2021 net margin 9.1%FY2022 net margin 4.4%FY2023 net margin 9.9%FY2024 net margin 9.0%FY2025 net margin 12.3%FY2026 net margin 7.3% FY2017FY2026
Revenue$1.3B Growth−2.0% Net margin7.3%
PGNYProgyny, Inc.
FY2017 revenue $48.6MFY2018 revenue $105.4MFY2019 revenue $229.7MFY2020 revenue $344.9MFY2021 revenue $500.6MFY2022 revenue $786.9MFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.3B FY2017 net margin −25.6%FY2018 net margin 0.6%FY2019 net margin −3.7%FY2020 net margin 13.5%FY2021 net margin 13.1%FY2022 net margin 3.9%FY2023 net margin 5.7%FY2024 net margin 4.7%FY2025 net margin 4.5% FY2017FY2026
Revenue$1.3B Growth+10.4% Net margin4.5%
MDGLMadrigal Pharmaceuticals, Inc.
FY2024 revenue $180.1MFY2025 revenue $958.4M FY2024 net margin −258.6%FY2025 net margin −30.1% FY2017FY2026
Revenue$958.4M Growth+432% Net margin−30.1%
GHGuardant Health, Inc.
FY2017 revenue $49.8MFY2018 revenue $90.6MFY2019 revenue $214.4MFY2020 revenue $286.7MFY2021 revenue $373.7MFY2022 revenue $449.5MFY2023 revenue $563.9MFY2024 revenue $739.0MFY2025 revenue $982.0M FY2017 net margin −167.0%FY2018 net margin −93.8%FY2019 net margin −35.3%FY2020 net margin −88.5%FY2021 net margin −103.0%FY2022 net margin −145.6%FY2023 net margin −85.0%FY2024 net margin −59.0%FY2025 net margin −42.4% FY2017FY2026
Revenue$982.0M Growth+32.9% Net margin−42.4%
ADUSAddus HomeCare Corp
FY2017 revenue $426.0MFY2018 revenue $516.6MFY2019 revenue $648.8MFY2020 revenue $764.8MFY2021 revenue $864.5MFY2022 revenue $951.1MFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.4B FY2017 net margin 2.8%FY2018 net margin 3.2%FY2019 net margin 3.9%FY2020 net margin 4.3%FY2021 net margin 5.2%FY2022 net margin 4.8%FY2023 net margin 5.9%FY2024 net margin 6.4%FY2025 net margin 6.7% FY2017FY2026
Revenue$1.4B Growth+23.2% Net margin6.7%
LIVNLivaNova PLC
FY2017 revenue $1.0BFY2018 revenue $1.1BFY2019 revenue $1.1BFY2020 revenue $934.2MFY2021 revenue $1.0BFY2022 revenue $1.0BFY2023 revenue $1.2BFY2024 revenue $1.3BFY2025 revenue $1.4B FY2017 net margin −2.5%FY2018 net margin −17.1%FY2019 net margin −14.5%FY2020 net margin −37.3%FY2021 net margin −13.1%FY2022 net margin −8.4%FY2023 net margin 1.5%FY2024 net margin 5.0%FY2025 net margin −17.5% FY2017FY2026
Revenue$1.4B Growth+10.7% Net margin−17.5%
INSMINSMED Inc
FY2018 revenue $9.8MFY2019 revenue $136.5MFY2020 revenue $164.4MFY2021 revenue $188.5MFY2022 revenue $245.4MFY2023 revenue $305.2MFY2024 revenue $363.7MFY2025 revenue $606.4M FY2019 net margin −186.4%FY2020 net margin −178.9%FY2021 net margin −230.6%FY2022 net margin −196.3%FY2023 net margin −245.6%FY2024 net margin −251.2%FY2025 net margin −210.5% FY2017FY2026
Revenue$606.4M Growth+66.7% Net margin−210.5%
SHCSotera Health Co
FY2019 revenue $778.3MFY2020 revenue $818.2MFY2021 revenue $931.5MFY2022 revenue $1.0BFY2023 revenue $1.0BFY2024 revenue $1.1BFY2025 revenue $1.2B FY2019 net margin −2.7%FY2020 net margin −4.7%FY2021 net margin 12.5%FY2022 net margin −23.3%FY2023 net margin 4.9%FY2024 net margin 4.0%FY2025 net margin 6.7% FY2017FY2026
Revenue$1.2B Growth+5.7% Net margin6.7%
TECHBio-Techne
FY2017 revenue $563.0MFY2018 revenue $643.0MFY2019 revenue $714.0MFY2020 revenue $738.7MFY2021 revenue $931.0MFY2022 revenue $1.1BFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.2BFY2026 revenue $1.2B FY2017 net margin 13.5%FY2018 net margin 19.6%FY2019 net margin 13.5%FY2020 net margin 31.0%FY2021 net margin 15.1%FY2022 net margin 24.6%FY2023 net margin 25.1%FY2024 net margin 14.5%FY2025 net margin 6.0%FY2026 net margin 15.0% FY2017FY2026
Revenue$1.2B Growth−0.4% Net margin15.0%
PENPenumbra Inc
FY2017 revenue $333.8MFY2018 revenue $444.9MFY2019 revenue $547.4MFY2020 revenue $560.4MFY2021 revenue $747.6MFY2022 revenue $847.1MFY2023 revenue $1.1BFY2024 revenue $1.2BFY2025 revenue $1.4B FY2017 net margin 1.4%FY2018 net margin 1.5%FY2019 net margin 8.9%FY2020 net margin −2.8%FY2021 net margin 0.7%FY2022 net margin −0.2%FY2023 net margin 8.6%FY2024 net margin 1.2%FY2025 net margin 12.7% FY2017FY2026
Revenue$1.4B Growth+17.5% Net margin12.7%

Who rewrote the most

Share of the words changed in Risk Factors and in MD&A, latest 10-K against the one before

Risk FactorsMD&AEach company's latest 10-K, so the dates differ. A company that rewrote much may have reorganized the text.

Revenue, FY2017 to FY2026

Revenue as reported in the 10-K.

$0 $1.4B FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: $48.6M, $105.4M, $229.7M, $344.9M, $500.6M, $786.9M, $1.1B, $1.2B, $1.3B, - PGNY MDGL: $0, $0, $0, $0, $0, $0, $0, $180.1M, $958.4M, - MDGL GH: $49.8M, $90.6M, $214.4M, $286.7M, $373.7M, $449.5M, $563.9M, $739.0M, $982.0M, - GH ADUS: $426.0M, $516.6M, $648.8M, $764.8M, $864.5M, $951.1M, $1.1B, $1.2B, $1.4B, - ADUS LIVN: $1.0B, $1.1B, $1.1B, $934.2M, $1.0B, $1.0B, $1.2B, $1.3B, $1.4B, - LIVN INSM: $0, $9.8M, $136.5M, $164.4M, $188.5M, $245.4M, $305.2M, $363.7M, $606.4M, - INSM SHC: -, -, $778.3M, $818.2M, $931.5M, $1.0B, $1.0B, $1.1B, $1.2B, - SHC TECH: $563.0M, $643.0M, $714.0M, $738.7M, $931.0M, $1.1B, $1.1B, $1.2B, $1.2B, $1.2B TECH PEN: $333.8M, $444.9M, $547.4M, $560.4M, $747.6M, $847.1M, $1.1B, $1.2B, $1.4B, - PEN HAE: $886.1M, $903.9M, $967.6M, $988.5M, $870.5M, $993.2M, $1.2B, $1.3B, $1.4B, $1.3B HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from $0 to $1.4B. A gap is a year with no number. A ring marks where a line starts: SHC has no earlier 10-K here.

Sales growth, FY2017 to FY2026

Revenue against the fiscal year before.

−13.8% +432% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: -, +117%, +118%, +50.1%, +45.2%, +57.2%, +38.3%, +7.2%, +10.4%, - PGNY MDGL: -, -, -, -, -, -, -, -, +432%, - MDGL GH: +97.4%, +81.9%, +137%, +33.8%, +30.3%, +20.3%, +25.5%, +31.0%, +32.9%, - GH ADUS: +6.3%, +21.3%, +25.6%, +17.9%, +13.0%, +10.0%, +11.3%, +9.1%, +23.2%, - ADUS LIVN: +4.9%, +9.4%, −2.1%, −13.8%, +10.8%, −1.3%, +12.9%, +8.7%, +10.7%, - LIVN INSM: -, -, n/m, +20.5%, +14.6%, +30.2%, +24.4%, +19.2%, +66.7%, - INSM SHC: -, -, -, +5.1%, +13.9%, +7.8%, +4.5%, +4.9%, +5.7%, - SHC TECH: +12.8%, +14.2%, +11.0%, +3.5%, +26.0%, +18.7%, +2.8%, +2.0%, +5.2%, −0.4% TECH PEN: +26.8%, +33.3%, +23.0%, +2.4%, +33.4%, +13.3%, +25.0%, +12.9%, +17.5%, - PEN HAE: -, +2.0%, +7.0%, +2.2%, −11.9%, +14.1%, +17.7%, +12.0%, +4.0%, −2.0% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −13.8% to +432%. A gap is a year with no number. A ring marks where a line starts: HAE, PGNY, MDGL, INSM, SHC have no earlier 10-K here.

Gross margin, FY2017 to FY2026

Gross profit / revenue.

15.2% 82.3% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: 15.2%, 18.4%, 19.8%, 20.3%, 22.4%, 21.3%, 21.9%, 21.7%, 23.6%, - PGNY ADUS: 27.2%, 26.5%, 27.6%, 29.6%, 31.2%, 31.5%, 32.1%, 32.5%, 32.5%, - ADUS LIVN: 64.4%, -, 66.8%, 63.7%, 68.2%, 69.2%, 65.5%, 68.1%, 67.7%, - LIVN INSM: -, 75.4%, 82.3%, -, -, -, -, -, -, - INSM SHC: -, -, 50.8%, 54.2%, 55.7%, 55.5%, 55.0%, 54.7%, 55.5%, - SHC TECH: 66.5%, 67.2%, 66.3%, 65.4%, 68.0%, 68.4%, 67.7%, 66.4%, 64.8%, 65.8% TECH PEN: 65.1%, 65.7%, 68.0%, 60.3%, 63.6%, 63.2%, 64.5%, 63.2%, 67.1%, - PEN HAE: 42.7%, 45.6%, 43.2%, 49.0%, 45.7%, 50.9%, 52.6%, 52.8%, 55.0%, 59.0% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 15.2% to 82.3%. A gap is a year with no number. A ring marks where a line starts: INSM, SHC have no earlier 10-K here.

Operating margin, FY2017 to FY2026

Operating income / revenue.

−276.4% 27.6% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: −22.7%, −3.3%, 4.2%, 2.4%, 6.5%, 3.0%, 5.7%, 5.8%, 6.6%, - PGNY MDGL: -, -, -, -, -, -, -, −276.4%, −31.3%, - MDGL GH: −153.7%, −102.5%, −38.4%, −88.9%, −110.0%, −121.1%, −100.1%, −60.0%, −44.5%, - GH ADUS: 5.9%, 4.4%, 5.4%, 5.8%, 7.6%, 7.2%, 8.6%, 8.9%, 9.7%, - ADUS LIVN: 9.5%, −22.4%, −15.8%, −29.3%, −0.1%, −7.5%, −5.9%, 10.3%, 14.4%, - LIVN INSM: -, n/m, −172.4%, −161.3%, −199.0%, −186.4%, −232.5%, −241.5%, −205.6%, - INSM SHC: -, -, 23.6%, 25.2%, 27.6%, 24.7%, 26.4%, 27.0%, -, - SHC TECH: 21.4%, 21.2%, 20.5%, 21.3%, 25.5%, 26.8%, 26.3%, 17.8%, 8.4%, 20.7% TECH PEN: 0.3%, −0.2%, 8.7%, −6.9%, −1.0%, 0.7%, 6.9%, 0.8%, 13.5%, - PEN HAE: −2.2%, 6.2%, 8.6%, 10.5%, 10.3%, 8.1%, 13.4%, 12.6%, 16.3%, 11.7% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −276.4% to 27.6%. A gap is a year with no number. A ring marks where a line starts: MDGL, INSM, SHC have no earlier 10-K here.

Net margin, FY2017 to FY2026

Net income / revenue.

−258.6% 31.0% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: −25.6%, 0.6%, −3.7%, 13.5%, 13.1%, 3.9%, 5.7%, 4.7%, 4.5%, - PGNY MDGL: -, -, -, -, -, -, -, −258.6%, −30.1%, - MDGL GH: −167.0%, −93.8%, −35.3%, −88.5%, −103.0%, −145.6%, −85.0%, −59.0%, −42.4%, - GH ADUS: 2.8%, 3.2%, 3.9%, 4.3%, 5.2%, 4.8%, 5.9%, 6.4%, 6.7%, - ADUS LIVN: −2.5%, −17.1%, −14.5%, −37.3%, −13.1%, −8.4%, 1.5%, 5.0%, −17.5%, - LIVN INSM: -, n/m, −186.4%, −178.9%, −230.6%, −196.3%, −245.6%, −251.2%, −210.5%, - INSM SHC: -, -, −2.7%, −4.7%, 12.5%, −23.3%, 4.9%, 4.0%, 6.7%, - SHC TECH: 13.5%, 19.6%, 13.5%, 31.0%, 15.1%, 24.6%, 25.1%, 14.5%, 6.0%, 15.0% TECH PEN: 1.4%, 1.5%, 8.9%, −2.8%, 0.7%, −0.2%, 8.6%, 1.2%, 12.7%, - PEN HAE: −3.0%, 5.0%, 5.7%, 7.7%, 9.1%, 4.4%, 9.9%, 9.0%, 12.3%, 7.3% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −258.6% to 31.0%. A gap is a year with no number. A ring marks where a line starts: MDGL, INSM, SHC have no earlier 10-K here.

Free cash flow, FY2017 to FY2026

Cash from operations minus capital spending.

−$967.6M $307.9M FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: −$10.1M, $1.7M, −$4.5M, $35.2M, $23.9M, $77.2M, $185.2M, $173.7M, $191.8M, - PGNY MDGL: −$22.4M, −$25.5M, −$41.8M, −$157.9M, −$184.1M, −$225.1M, −$325.7M, −$457.0M, −$190.0M, - MDGL GH: −$78.9M, −$92.4M, −$65.9M, −$140.1M, −$284.1M, −$386.9M, −$345.5M, −$274.9M, −$233.1M, - GH ADUS: $49.2M, $27.9M, $7.4M, $102.6M, $34.8M, $96.8M, $102.8M, $110.4M, $103.8M, - ADUS LIVN: $58.4M, $83.3M, −$115.8M, −$114.4M, $77.1M, $43.4M, $39.9M, $135.9M, $173.3M, - LIVN INSM: −$162.6M, −$271.1M, −$292.9M, −$225.6M, −$370.6M, −$410.3M, −$549.5M, −$705.8M, −$967.6M, - INSM SHC: -, -, $91.8M, $67.1M, $179.4M, $95.6M, −$362.7M, $45.1M, $149.2M, - SHC TECH: $128.5M, $149.4M, $156.2M, $153.5M, $307.9M, $280.4M, $216.1M, $236.1M, $256.6M, $263.2M TECH PEN: $159K, $19.2M, $4.5M, −$58.0M, −$11.7M, −$75.0M, $82.1M, $147.3M, $174.9M, - PEN HAE: $83.6M, $145.6M, $40.3M, $109.5M, $71.8M, $75.8M, $81.7M, $143.6M, $142.4M, $260.4M HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$967.6M to $307.9M. A gap is a year with no number. A ring marks where a line starts: SHC has no earlier 10-K here.

FCF margin, FY2017 to FY2026

Free cash flow / revenue.

−253.7% 33.1% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: −20.8%, 1.6%, −2.0%, 10.2%, 4.8%, 9.8%, 17.0%, 14.9%, 14.9%, - PGNY MDGL: -, -, -, -, -, -, -, −253.7%, −19.8%, - MDGL GH: −158.3%, −101.9%, −30.7%, −48.9%, −76.0%, −86.1%, −61.3%, −37.2%, −23.7%, - GH ADUS: 11.5%, 5.4%, 1.1%, 13.4%, 4.0%, 10.2%, 9.7%, 9.6%, 7.3%, - ADUS LIVN: 5.8%, 7.5%, −10.7%, −12.3%, 7.4%, 4.2%, 3.5%, 10.8%, 12.5%, - LIVN INSM: -, n/m, −214.6%, −137.2%, −196.6%, −167.2%, −180.1%, −194.1%, −159.6%, - INSM SHC: -, -, 11.8%, 8.2%, 19.3%, 9.5%, −34.6%, 4.1%, 12.8%, - SHC TECH: 22.8%, 23.2%, 21.9%, 20.8%, 33.1%, 25.4%, 19.0%, 20.4%, 21.0%, 21.7% TECH PEN: 0.0%, 4.3%, 0.8%, −10.3%, −1.6%, −8.8%, 7.8%, 12.3%, 12.5%, - PEN HAE: 9.4%, 16.1%, 4.2%, 11.1%, 8.2%, 7.6%, 7.0%, 11.0%, 10.5%, 19.5% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −253.7% to 33.1%. A gap is a year with no number. A ring marks where a line starts: MDGL, INSM, SHC have no earlier 10-K here.

Return on equity, FY2017 to FY2026

Net income / shareholders' equity at the year end.

−172.8% 27.8% FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: n/m, n/m, −7.5%, 27.8%, 26.1%, 8.1%, 11.2%, 12.9%, 11.3%, - PGNY MDGL: −17.1%, −6.9%, −20.2%, −84.3%, −123.3%, −149.6%, −92.2%, −61.8%, −47.8%, - MDGL GH: −27.0%, −17.6%, −9.5%, −19.5%, −59.7%, n/m, n/m, n/m, n/m, - GH ADUS: 7.0%, 6.1%, 5.3%, 6.4%, 7.9%, 7.3%, 8.8%, 7.6%, 8.8%, - ADUS LIVN: −1.4%, −12.6%, −11.4%, −31.4%, −10.5%, −7.1%, 1.4%, 4.8%, −20.2%, - LIVN INSM: −53.4%, −155.7%, −97.2%, −106.6%, −105.9%, n/m, n/m, n/m, −172.8%, - INSM SHC: -, -, n/m, −8.5%, 19.9%, −66.7%, 11.6%, 11.0%, 12.9%, - SHC TECH: 8.0%, 11.7%, 8.2%, 16.6%, 9.0%, 16.0%, 14.5%, 8.1%, 3.8%, 8.6% TECH PEN: 1.2%, 1.6%, 10.0%, −2.4%, 0.6%, −0.2%, 7.7%, 1.2%, 12.4%, - PEN HAE: −3.6%, 6.1%, 8.2%, 13.0%, 10.9%, 5.8%, 14.1%, 12.2%, 20.4%, 12.2% HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −172.8% to 27.8%. A gap is a year with no number. A ring marks where a line starts: PGNY, SHC have no earlier 10-K here.

Debt / equity, FY2017 to FY2026

Total debt / shareholders' equity at the year end.

0.00 13.12 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 MDGL: -, -, -, -, 0.00, 0.35, 0.28, 0.16, 0.56, - MDGL ADUS: 0.25, 0.06, 0.13, 0.38, 0.38, 0.21, 0.18, 0.23, 0.11, - ADUS LIVN: 0.08, 0.11, 0.25, 0.59, 0.19, 0.45, 0.46, 0.48, 0.31, - LIVN INSM: 0.15, 2.16, 1.72, 1.63, 1.95, 13.12, n/m, 3.93, 0.74, - INSM SHC: -, -, -, 4.03, 2.97, 5.55, 5.02, 5.49, 3.53, - SHC TECH: 0.36, 0.31, 0.43, 0.26, 0.22, 0.15, 0.18, 0.15, 0.18, 0.09 TECH HAE: 0.43, 0.34, 0.52, 0.65, 0.97, 1.03, 0.94, 0.84, 1.49, 1.56 HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from 0.00 to 13.12. A gap is a year with no number. A ring marks where a line starts: MDGL, SHC have no earlier 10-K here.
CompanyFY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
HAE Mar 0.430.340.520.650.971.030.940.841.491.56
PGNY Dec -n/m--------
MDGL Dec ----0.000.350.280.160.56-
GH Dec -------n/mn/m-
ADUS Dec 0.250.060.130.380.380.210.180.230.11-
LIVN Dec 0.080.110.250.590.190.450.460.480.31-
INSM Dec 0.152.161.721.631.9513.12n/m3.930.74-
SHC Dec ---4.032.975.555.025.493.53-
TECH Jun 0.360.310.430.260.220.150.180.150.180.09
PEN Dec ----------
Peer median0.200.210.340.590.300.400.280.350.44-

EPS (diluted), FY2017 to FY2026

Diluted earnings per share, on today's share count after splits.

−$21.90 $5.22 FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026 PGNY: −$2.37, $0.04, −$0.41, $0.47, $0.66, $0.30, $0.62, $0.57, $0.65, - PGNY MDGL: −$2.54, −$2.22, −$5.45, −$13.09, −$14.63, −$17.23, −$19.99, −$21.90, −$12.85, - MDGL GH: −$7.07, −$2.80, −$0.84, −$2.60, −$4.00, −$6.41, −$4.28, −$3.56, −$3.32, - GH ADUS: $1.03, $1.33, $1.77, $2.08, $2.81, $2.84, $3.83, $4.23, $5.22, - ADUS LIVN: −$0.52, −$3.91, −$3.26, −$7.18, −$2.68, −$1.61, $0.32, $1.16, −$4.45, - LIVN INSM: −$2.89, −$4.22, −$3.01, −$3.01, −$3.88, −$3.91, −$5.34, −$5.57, −$6.42, - INSM SHC: -, -, −$0.09, −$0.16, $0.41, −$0.83, $0.18, $0.16, $0.27, - SHC TECH: $0.51, $0.83, $0.62, $1.46, $0.87, $1.66, $1.76, $1.05, $0.46, $1.16 TECH PEN: $0.13, $0.18, $1.34, −$0.44, $0.14, −$0.05, $2.32, $0.36, $4.52, - PEN HAE: −$0.51, $0.85, $1.04, $1.48, $1.55, $0.84, $2.24, $2.29, $3.31, $2.05 HAE
HAE is the bold green line; each peer has its own colour and dash, named at the line's end. One scale from −$21.90 to $5.22. A gap is a year with no number. A ring marks where a line starts: SHC has no earlier 10-K here.

Fiscal years are lined up as each company's 10-K names them; the month next to a ticker is when its year ends. Hover a number for the XBRL line items and the filing; click it to open the filing on sec.gov. "n/m" means not meaningful: equity below zero, or a base so close to zero that the ratio says nothing. The peer median leaves out HAE and needs at least three peers with the number. P/E, P/S and P/FCF at each year end appear here once the site has daily prices. What the same companies write about AI, tariffs and more

Sources

Each company's 10-K, from SEC's XBRL company facts. Every number links to its filing in the Inline XBRL viewer.

Also

Financials: HAE's own statements, year by year. Compare: the whole peer group on one page.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/HAE/export.csv") into a cell.

Next:Industry numbers
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.